---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-26-012287"
form_type: "8-K"
ticker: "ADCT"
cik: "0001771910"
company_name: "ADC Therapeutics SA"
filed_at: "2026-08-13T13:14:34+00:00"
generated_at: "2026-08-13T13:16:09.883561+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ADC Therapeutics Q2 revenue $18.6M; FDA flags LOTIS-5 benefit-risk concerns

## Summary
- Q2 net product revenue $18.6M vs $18.1M YoY; six-month revenue $38.7M vs $35.5M.
- Q2 net loss $16.6M ($0.11/share) vs $56.6M loss in 2025; adjusted net loss $16.3M.
- Cash $219.1M at June 30, 2026; runway at least into 2028.
- FDA pre-sBLA meeting cited Grade 5 event imbalance and marginal benefit; regulatory path under review.
- 17% workforce cut yields ~$10M annual savings; LOTIS-7 enrollment complete at 100 patients.

## SEC filing metadata
- accession: 0000950103-26-012287
- form_type: 8-K
- ticker: ADCT
- cik: 0001771910
- company_name: ADC Therapeutics SA
- filed_at: 2026-08-13T13:14:34+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1771910/000095010326012287/0000950103-26-012287-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1771910/000095010326012287/dp251718_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-26-012287
- JSON: https://secwatch.observer/filing/0000950103-26-012287.json
- Plain text: https://secwatch.observer/filing/0000950103-26-012287.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.